Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001493152-24-018805

← back to feed
Filed
May 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 13, 2024 172.32M sh
Cash And Equivalents Q1 2024 · Mar 31, 2024 $7.68M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $8.84M
Current Liabilities Q1 2024 · Mar 31, 2024 $155.85K
Current Liabilities Q1 2024 · Dec 31, 2023 $665.16K
Total Liabilities Q1 2024 · Mar 31, 2024 $3.16M
Total Liabilities Q1 2024 · Dec 31, 2023 $3.67M
Current Assets Q1 2024 · Mar 31, 2024 $7.79M
Current Assets Q1 2024 · Dec 31, 2023 $8.95M
Total Assets Q1 2024 · Mar 31, 2024 $7.79M
Total Assets Q1 2024 · Dec 31, 2023 $8.95M
Shares Diluted Q1 2024 · Mar 31, 2023 171.79M sh
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$757.28K
Stockholders Equity Q1 2024 · Mar 31, 2023 $7.76M
Stockholders Equity Q1 2024 · Dec 31, 2022 $8.3M
Eps Diluted Q1 2024 · Mar 31, 2023 $0.00
Eps Basic Q1 2024 · Mar 31, 2023 $0.00
Sga Expense Q1 2024 · Mar 31, 2023 $428.33K
Rd Expense Q1 2024 · Mar 31, 2023 $201.4K
Net Income Q1 2024 · Mar 31, 2023 −$539.6K
Operating Income Q1 2024 · Mar 31, 2023 −$629.72K